aberrations.112 Last but not least, the alternative BTK inhibitor acalabrutinib was just lately authorised from the FDA (not because of the EMA yet) as frontline therapy in look at of the results of the phase III trial evaluating acalabrutinib compared toVenetoclax is probably the greatest alternate options in this example, including people with su